Navigation Links
Haemacure to Present at the BioInternational Convention - The Global Event for Biotechnology - at the San Diego Convention Centre, California, from June 17 - 20, 2008
Date:6/13/2008

HAE:TSX

MONTREAL, June 13 /PRNewswire-FirstCall/ - Haemacure Corporation (TSX : HAE), a Montreal-based specialty bio-therapeutics company developing high-value human plasma-derived protein products for commercialization, announced today that Joseph Galli, Chairman and Chief Executive Officer, will present Haemacure and give an update on the Company's major milestone achievements at the Bio International Convention - The Global Event for Biotechnology. The presentation will take place on Thursday, June 19th, at 1:30 pm (PDT), in Room 3, of the San Diego Convention Centre.

About Haemacure

Haemacure Corporation is a specialty biotherapeutics company developing high-value human plasma-derived protein products for commercialization. Haemacure's research and development effort is driven by its proprietary plasma protein extraction technology to develop next-generation products, including surgical hemostats. Haemacure's lead product candidate, Hemaseel(R)HMN, is a fibrin sealant planned to enter pivotal Phase II/Phase III clinical trials during the first quarter of 2009. Haemacure's second product candidate is thrombin, a component of its fibrin sealant, now in preclinical stage. Follow-on development will focus on surgical hemostats, wound healing, adhesion prevention, regenerative medecine, drug delivery and combination with biomaterials. Haemacure has discovered eleven additional specialty proteins and enzymes in one if its two plasma fractions and seeks to advance these proteins and enzymes through partnerships with pharmaceutical and biotechnology companies. Haemacure operates offices in Sarasota, Florida through a wholly-owned subsidiary. The Corporation is traded under stock symbol HAE on the TSX.


'/>"/>
SOURCE HAEMACURE CORPORATION
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Haemacure Reports Third Quarter 2007 Results
2. Haemacure Adopts Strategy for "First-Patient-In" Fibrin Sealant Pivotal Clinical Trials
3. Haemacure announces webcast of presentation at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conferencec
4. Haemacure Announces Details of its Annual General and Special Meeting of Shareholders
5. Media Invitation - Annual General and Special Meeting of Shareholders of Haemacure
6. Haemacure Reports on its annual general and special meeting of shareholders
7. Haemacure Discloses Positive Results of a preclinical study of its fibrin sealant in adhesion prevention and opens a new opportunity in a market with a significant unmet medical need
8. Haemacure to Present at the BioFinance 2008 Conference to be held at the Toronto Marriott Eaton Centre, May 6 - 8, 2008
9. Haemacure financing receives shareholder consent - Series B Warrants are amended
10. Haemacure announces webcast of presentation at Rodman & Renshaw 5th Annual Global Healthcare Conference
11. Haemacure to Present at Busines$ Meets Finance on May 20, 2008 at the Montreal Sheraton Centre
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... 18, 2017 , ... “Beyond Our Imaginations: The Infinite God”: shows the importance ... God” is the creation of published author, Mark Lawrence, born in Michigan, the author ... problem with becoming a greater man of God is that I have to be ...
(Date:8/18/2017)... ... ... “Kingdom Mandate for Kingdom Builders”: a call to walk as citizens of ... the creation of published author, John F. McGeorge, Jr. Dr. John F. McGeorge ... He spent three decades training pastors and Christian leaders. He also met ...
(Date:8/18/2017)... ... , ... “Case #10-5411 Veterans Administration”: a personal account of ... Veterans Administration” is the creation of published author, Carol Mulhern, single mother of ... started work at the Coatesville VAMC as a file clerk then later became ...
(Date:8/17/2017)... ... 2017 , ... The award-winning producers of the Innovations with ... for Therapeutic Recreation Certification (NCTRC), slated to air nationwide, fourth quarter 2017. Check ... non-profit, international organization dedicated to professional excellence for the protection of consumers through ...
(Date:8/17/2017)... ... August 17, 2017 , ... CARF International announced that ... its residential drug and alcohol detox program. This accreditation decision represents the highest ... organization’s substantial conformance to the CARF standards. , Behavioral health organizations receiving a ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... , Aug. 15, 2017  AOTI Inc. announced today that its ... Inc., has recently opened a New York City Office in ... of its unique Topical Wound Oxygen (TWO 2 ) homecare therapy. ... Accreditation Commission for Health Care (ACHC) under the company,s DMEPOS accreditation ... ...
(Date:8/8/2017)...   Second-quarter 2017 revenues of ... share from continuing operations ... to $110 million Second-quarter ... million Second-quarter 2017 adjusted ... 8 percent to $0.93 ...
(Date:8/7/2017)...  Endo International plc (NASDAQ: ENDP ) ... all known U.S. mesh product liability claims and that ... remaining U.S. claims at reasonable values. Under the agreements, ... quarter of 2017 and continuing through the fourth quarter ... results, the Company intends to increase its mesh product ...
Breaking Medicine Technology: